Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?

• by Cecilia Lina Pugliano, Raymond Fueng-Hin Liang, Andrea Ruffa, Marietta Iacucci, Subrata Ghosh

• August 1, 2025

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

• by Doug Brunk

• February 19, 2026

• 2 min

Melatonin-induced restoration of the intestinal mucosal barrier in inflammatory bowel disease via activation of the SIRT1-LKB1-pAMPK axis

• by Qingyi Mao, Beibei Lin, Wenhao Xia, Yu Zhang, Yue Lei, Qian Cao, Mengque Xu

• May 5, 2026

Severity of surgical histopathological fibrosis predicted postoperative recurrence in Crohn’s disease: a multi-center retrospective cohort study

• by Xinyu Wang, Yiwen Tu, Shuowen Zhang, Tianyi Che, Shenglan You, Weitong Gao, Lingying Zhao, Ren Mao, Jing Sun, Yubei Gu, Yao Zhang, Zirui He, Yi Li, Duowu Zou

• February 26, 2026